As per our research, digital therapeutic solutions for metabolic disorders are likely to capture major share (XX%) of the overall market in 2020. This can be attributed to the fact that majority of the solutions are being developed for people with diabetes. This is followed by the solutions developed for mental health problems and substance use disorders. However, given the fact that a significant number of the solutions are being developed for patients with neurological disorders, solutions for such disorders are anticipated to hold a significant share in the market, in 2030. To Request for Sample report - https://www.rootsanalysis.com/reports/208/request-sample.html Furthermore, according to a recent article published by Evidera, the maximum number of clinical trials (related to digital therapeutics) were conducted for psychiatric indications (25%). These trials also provide a strong evidence supporting digital cognitive behavior therapy’s efficacy in this area. This is followed by trials for evaluating digital therapeutics for cardiovascular (11%), endocrine (10%), addiction (10%), neurology (8%), and respiratory (7%) disorders. In terms of business model adopted, we observed that within digital therapeutics market, majority of the revenues are generated from the sales of the products through B2B channel. This can be attributed to the fact that majority of these digital therapeutic solutions require physicians’ prescription for sale. Further, majority of the companies that have not marketed their solutions rely on this approach to distribute their products to different patient groups. To Request for customize report - https://www.rootsanalysis.com/reports/208/request-customization.html In fact, in an interview with the Vice-President of marketing of an industry player, she stated that “The USFDA has approved digital therapeutics as a prescription only product with clearly defined usage parameters. As per the definition, a product can only be called digital therapeutics if it has been built on clinical guidelines and has been able to demonstrate clinical effectiveness. By this measure, it has a therapeutic impact on the body. This means that it must be prescribed by a doctor directly or as part of a combination used with a drug or medical device. It is for this reason that B2B offerings should account for closer to 80-90% of the market currently.” To request for report, click under - Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 You may also be interested in the following titles: 1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 2. Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 Contact Details Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Roots Analysis Web: https://www.rootsanalysis.com/ LinkedIn: https://in.linkedin.com/company/roots-analysis Twitter: https://twitter.com/RootsAnalysis.com Medium: https://medium.com/@RootsAnalysis Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/ Quora: https://rootsanalysisinsights.quora.com/
Topics
